Abstract
INTRODUCTION
Cancer is a major threat to public health in the 21 st century and one of the leading causes of death world wide. However, the mechanisms of carcinogenesis, cancer invasion, and metastasis remain unclear [1] . Colorectal cancer is the third most common cancer worldwide. Approximately 25% of patients with colorectal cancer present with overt metastatic disease; metastatic disease develops in 40% to 50% of newly diagnosed patients [2] . The clinical need for imagebased detection and monitoring for effective therapeutic management to reduce the mortality caused by this disease has not been met to date. Therefore, novel strategies and treatment concepts are needed, particularly because conventional cancer therapies, such as external radiation and chemotherapy, have problems such as poor specificity. These conventional therapies often cause doselimiting side effects and inhibit the possibility of curative treatments.
Nanomedicine has exploited the possibility of designing tumortargeted nanocarriers that can deliver radionuclide payloads in a site or moleculeselective manner based on their magnetic properties, thereby improving the effectiveness and safety of cancer molecular imaging and therapies. Many studies have proven the feasibility of the use of targeted nanoparticle probes. Nanotechnology can lead to fundamental changes and improve the current understanding of biological processes in health and disease as well as enable novel diagnostics and therapeutics for treating cancer; consequently, advances made on the basis of nanotechnology could lead to progress in healthcare [3] . Targeted drug delivery systems, such as passive and active targeting nanoparticles or nanocarriers, have been developed to improve the biodistribution, pharmacological, therapeutic, and toxic properties of chemical agents used in cancer diagnostics and therapeutics [4] . The abundant expression and signal amplification properties of these targets are mandatory for successful receptortargeted tumor imaging and for their subsequent clinical translation [5] . The epidermal growth factor receptor (EGFR) is a transmembrane receptor belonging to the ErbB family of receptors; the EGFR family includes four transmembrane receptors, namely, EGFR, HER2, HER3, and HER4 [6] . EGFR is a cell surface receptor that plays a key role in signaling pathways, and such pathways regulate cell prolife ration, angiogenesis, and tumor metastasis [7, 8] . Previous studies reported that EGFR is widely overexpressed 131 I-antiEGFR-BSA-PCL was markedly taken up by the tumor and reached its maximal uptake value of 21.0 ± 1.01 %ID/g (%ID/g is the percentage injected dose per gram of tissue) at 72 h following therapy; the drug concentration in the tumor was higher than that in the liver, heart, colon, or spleen. Tumor size measurements showed that tumor development was significantly inhibited by treatments with 131 I-antiEGFR-BSA-PCL and 131 I-BSA-PCL. The volume of tumor increased, and treatment rate with 131 I-antiEGFR-BSA-PCL was 124% ± 7%, lower than that with 131 I-BSA-PCL (127% ± 9%),
131
I (143% ± 7%), and normal saline (146% ± 10%). The percentage losses in original body weights were 39% ± 3%, 41% ± 4%, 49% ± 5%, and 55% ± 13%, respectively. The best survival and cure rates were obtained in the group treated with in several tumor types, including breast cancer, mela noma, brain glioblastoma, nonsmall cell lung cancer [9] , and colorectal cancer [10] ; thus, EGFR is an attractive candidate for anticancer therapy.
Several radionuclides have been surfacebiocon jugated or afterloaded in nanoparticles to improve their effectiveness and reduce the toxicity of cancer imaging and therapies in preclinical and clinical studies. In the broad spectrum of available radionuclides,  beta emitters such as   90   Y,   131   I, and   177 Lu are the most commonly used for targeted therapies [11] . 131 I provides imaging feasibility and betaemitting therapeutic effects [12] . The application of nanotechnology for the diagnosis and treatment of colorectal cancer has the potential to improve conventional methods as well as help with the development of novel approaches for detection and therapy [13] . In the present study, 131 IantiEGFRBSAPCL and 131 IBSAPCL were successfully synthesized. These liposomes were characterized for cellular uptake, timedependent uptake of 131 I by LS180 cells in vitro, therapeutic efficacy, histopathology, tissue distribution, and SPECT imaging in an LS180 xenografted nude mouse model.
MATERIALS AND METHODS

Materials
The following reagents and materials used in this study were obtained: Minimum Essential Medium Eagles with Earle's Balanced Salts (MEMEBSS; Gibco), fetal bovine serum (FBS; Gibco), rabbit polyclonal antihuman epidermal growth factor receptor antibody (Abcam, ab2430), 5 mg/mL monoclonal antibody (MERCK Inc., C225; cetuximab), and PV6000 Polymer Detection System (ZSGBBIO Co.).
Cell line
The colorectal cancer cell line LS180 was purchased from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/Peking Union Medical College (Beijing, China). The cells were maintained in MEMEBSS medium supplemented with 10% FBS and 1% penicillin/streptomycin. The LS180 cells were grown at 37 ℃ in a humidified incubator with a mixture of 95% air and 5% CO2.
Preparation of nanoparticles
The cetuximabdecorated, BSAPCLconjugated antiEGFRBSAPCL and BSAPCL liposomes were synthesized by the researchers from the Department of Polymer Materials Science and Engineering of Tianjin University [14] . The antiEGFRBSAPCL and BSA PCL liposomes were labeled with 131 I (Beijing Atomic Hitech Co., Ltd.) via the chloramine T method. A detailed description and biological characterization of the compounds are presented by Ickenstein et al [15] . The labeling rate and the radiochemical purity 
Liposomal targeting in EGFR-overexpressing LS180 cells
The cellular binding and uptake of the antiEGFR BSAPCL and BSAPCL liposomes were evaluated by confocal microscopy in LS180 cells. The antiEGFR BSAPCL and BSAPCL liposomes were first labeled by fluorescein isothiocyanate (FITC), then were added at a concentration of 1 mg/10 6 cells. The cell cultures were then incubated for 4 h at 37 ℃. After incubation, cells were washed thrice with PBS, fixed with 4% paraformaldehyde, and analyzed by confocal microscopy (laser scanning confocal microscope, Olympus FV1000; Japan). 
Animal model
Experimental subjects were fourweekold BALB/c female nude mice weighing 9 g to 11 g. These mice were purchased from the Beijing Experimental Animal Center of Peking Union Medical, China. Mice were kept under specific pathogenfree conditions, with a constant temperature of 25 ℃ to 27 ℃ and a constant humidity of 45% to 50% in the Laboratory Animal Center of the Tianjin Medical University, China. Animal experimentation guidelines were followed according to the regulations of Swiss veterinary law. [19] . SPECT imaging was performed at 4, 24, and 72 h after injection.
Animal care and use statement
We ensured that mouse use was conducted in accor dance with the highest scientific, humane, and ethical principles and was in compliance with regulations. We also ensured that housing conditions and care were species appropriate and that the environment was safe and secure for both animals and staff.
Statistical analysis
All in vitro experiments were performed in triplicate unless otherwise indicated. Statistical analyses were conducted with the SPSS software (version 17.0). The results are presented as the mean ± SD. Statistical significance was tested using Student's ttest or ANOVA, and Pvalues < 0.05 were considered statistically significant.
RESULTS
Basic properties of 131 I-BSA-PCL and 131 I-antiEGFR-BSA-PCL
The dynamic light scattering measurement showed that the average diameter of 131 IBSAPCL and
131
IantiEGFRBSAPCL was approximately 180 nm, and the polydispersity index was 0.164, in agreement with the TEM result. The mean ζ potential of the obtained proteinbased vesicle was also measured and was found to be 38.70 mV. The negative surface charge that resulted from the BSA shell could reduce undesired protein adsorption and provide good protection for the vesicle during the circulation in the body. I was approximately 50%85%, and the radiochemical purity was 95%98%.
Internalization of EGFR-BSA-PCL and BSA-PCL
The effective diameter of BSAPCL and antiEGFR BSAPCL was approximately 180 nm [14] . To assess the binding of antiEGFRBSAPCL and BSAPCL to LS180 cells with EGFR overexpression, confocal microscopy was used. The confocal images and the immuno fluorescence results of the LS180 cells incubated with antiEGFRBSAPCL and BSAPCL were compared ( Figure  1 ). antiEGFR-BSA-PCL was significantly internalized in the LS180 cells, which was shown by the appearance of strong green fluorescence. Compared with antiEGFR-BSAPCL, BSAPCL could similarly bind to cells, but the tumor retention was minimal, and the binding green fluorescence was weaker. This result suggests that the targeting ability of antiEGFRBSAPCL to tumor cells was enhanced by EGFR modification. The mice bearing human colorectal cancer were used for the biodistribution study at day 21 after tumor inoculation. The mice in each group were sacrificed at 4, 24, and 72 h post-injection of drugs, respectively. The heart, spleen, liver, colon, and tumor samples were collected for weighing and for radio activity measurements with a γ counter (LKB gamma 1261; LKB Instruments). %ID/g represents the percentage injected dose per gram of tissue. %ID/g was determined by the percentage of radioactivity contained within each gram of tissue compared to the total radioactivity injected into the body [16, 17] .
Meanwhile, the remaining spleen, liver, and tumor tissues were collected to study the histopathology of each group.
Therapeutic efficacy studies
Toxicity was monitored by measuring the body weight and tumor volume. During the course of treatment, the animal body weight and in vivo tumor growth were measured at day 21 after tumor cell inoculation. Mice were checked for survival every day; their body weight and tumor volume were measured every 3 d until the end of the study. The growth curve experiment was terminated at 54 d after tumor inoculation, and all mice were then sacrificed. After treatment, the length, width, and height of the tumors were measured with calipers once every 3 d. Tumor volume was calculated as follows: volume = 1/6 × π × length (cm) × width (cm) × height (cm) [18] .
Histopathology studies
The xenografted colorectal cancer cell line LS180 was characterized for EGFR overexpression by immunohistochemistry. For the immunohistochemical staining of EGFR, the rabbit polyclonal antihuman EGFR antibody (1:500) was used as the primary antibody, followed by PV 6000 via the twostep immuno histochemical detection of cellassociated EGFR. Mice from each group were sacrificed at 4, 24, and 72 h after the injection of different liposomes. The remaining spleen, liver, and tumor tissues were collected to study their histopathology. The organs from the four groups were dissected, fixed in 10% formalin for 48 h, embedded in paraffin, and sectioned. The sections (5-6 μm) were then stained with hematoxylin and eosin. The histopathological changes of the tissue were ultimately examined using light microscopy (Olympus × 40). 
SPECT whole-body imaging
Growth curves for nude mice
The trend of body weight growth for all study groups is shown in Figure 3 I, and normal saline demonstrated body weight losses of 39% ± 3%, 41% ± 4%, 49% ± 5%, and 55% ± 13%, respectively, on day 54 after tumor inoculation (P < 0.05).
Tumor volume of nude mice
Rapid tumor growth was observed in the xenografted colorectal cancer nude mice treated with saline or IBSAPCL, xenografted colorectal cancer tissues were histopathologically examined (Figure 7) . Upon comparison, a large field of the tumor tissue appeared necrotic. Evidence of dying tumor cells undergoing vacuolar degeneration of the cytoplasm was observed. Clusters of tumor cells decreased, whereas the intercellular space increased. Cellular arrangements were seen as discrete and not compact, and the cytoplasm was deeply stained. The cancerous nodes were characterized by patchy necrosis, and their tissue structure was smeared.
SPECT imaging
The SPECT images of LS180 tumorbearing mice (21 d after tumor inoculation) were acquired at different time points after the intratumor injection of 
DISCUSSION
Colorectal cancer is the third most common cancer worldwide [2] . The C26 murine colon carcinoma model has previously been reported to have a high level of metastasis that spreads after the intraperitoneal inoculation of tumor cells in BALB/c mice [20] . EGFR is a transmembrane receptor belonging to the ErbB family of receptors; the EGFR gene is activated or upregulated in 60% to 80% of colorectal cancer cases [6, 10] . Most of the normal tissues express very low levels of EGFR. However, the liver and kidney tissues express moderately high levels of the receptor, which can exceed that of tumors. Conventional anticancer drugs exhibit a lack of specificity, poor solubility and distribution, unfavorable pharmacokinetics, and hightissue damage or toxi city [21] . Radiation therapy is typically delivered through highenergy external beam radiation to irradiate the cancerous tissue. Liposomes are spherical vesicles formed by lipid bilayers. These structures have been widely investigated as carriers of tumortargeting therapy. Radioisotopes can be trapped within the inner space of the liposome, intercalated into the double membrane of the liposome, and connected with the surface of the liposome [22, 23] . However, given the close proximity of critical organs to the tumor, the delivery of a therapeutic dose of irradiation without causing serious complications is often impossible, even with technological advancements in radiation dose distribution, such as intensitymodulated radiation therapy [24, 25] . Tumortargeting therapy has overcome the lack of specificity of traditional therapeutic agents. Recent work comparing nontargeted and targeted nanoparticles (lipidbased [26] or polymerbased [27] ) has shown that the primary role of the targeting ligands is to enhance the cellular uptake of drugs by cancer cells rather than to increase their accumulation in the tumor. Kao et al [12] demonstrated the enhanced endocytosis and cytotoxicity of mouse model [12] . Chen et al [28] and Chang et al [19] reported the biodistribution, pharmacokinetics, and microSPECT/CT imaging of the 188 Reliposome in C26 colon carcinoma ascites and solid tumor animal models. Their results demonstrated the potential benefit and advantages of the 188 Reliposome in the C26 animal model. Bao et al [29] reported that the intratumoral injection of liposomal radionuclides had a slower clearance rate.
131
I is a radionuclide with a gamma emission of 364 keV (81.7%) and a beta emission of 0.606 MeV (89.9%). This molecule has the advantages of imaging feasibility and betaemitting therapeutic effects. In the present study, the initial treatment of colorectal cancer with Results with mouse models demonstrated the steady extravasation of nanoliposomes into ascites with the gradual release of the drug, followed by drug diffusion into the tumor cellular compartment [30, 31] . Wang et al [32] reported that direct intratumoral drug administration in advanced neck and head tumors was clearly appealing and immediately achieved high drug concentrations at the target sites without the associated side effects of external beam radiation or systemic chemotherapy. Their group also proved that direct injection could deliver drugs into areas of the tumor that had high interstitial pressure and large areas of avascular necrosis. This study was relevant to the present study on the pharmacokinetics and effectiveness of 131 IantiEGFRBSAPCL administration in the heart, liver, spleen, colon, and tumor cells. The observed iodine uptake demonstrated the potential benefits and advantages of 131 IantiEGFRBSAPCL in the LS180 animal model. The accumulation of radioactivity in the tumor was maintained at steady levels for at least 24 h.
SPECT imaging is a noninvasive imaging modality that can monitor the behavior of radiotherapeutics in the same animal at different time points. After the injection of different drugs, the SPECT imaging and iodine uptake showed that the tumor uptake of IantiEGFRBSAPCL had the tendency to spread into the tumor, liver, spleen, and urinary bladder area. We also observed that the nontumor tissues of the liver and spleen, which are reticuloendothelial systemrich organs, exhibited significant uptake of 131 IantiEGFRBSAPCL and 131 IBSAPCL. The remarkable accumulation of these compounds in the bladder implied that renal clearance is the predominant route of excretion of radioactive metabolites. A glutathionecoated luminescent gold nanoparticle (3 nm diameter) [33] and a gadolinium loaded dendrimerentrapped gold nanoparticle (90 nm mean diameter) [34] were previously reported to be excreted via the urinary system. Li et al [16] showed IBSAPCL. Therefore, the protocols used in this study revealed that the designed formulation and treatment trials were novel for a preclinical study.
In conclusion, the results of this study demon strated that IantiEGFRBSAPCL was effective in the killing of tumors, but we did not observe a radiation induced breakdown of the kidney and liver. Therefore, 131 IantiEGFRBSAPCL may be a safe drug for radiotherapy in colorectal cancer.
COMMENTS
Background
Epidermal growth factor receptor (EGFR) is a cell-surface receptor that plays a key role in signaling pathways. Such pathways regulate cell proliferation, angiogenesis, and tumor metastases. EGFR is widely overexpressed in several tumor types, including breast cancer, melanoma, brain glioblastoma, non-small cell lung cancer, and colorectal cancer. EGFR is an attractive candidate for anticancer therapy.
Research frontiers
Previous experiments have already proven that EGFR is widely overexpressed in colorectal cancer.
Innovations and breakthroughs
This is the first study evaluating the cellular binding and cellular uptake of 131 I-antiEGFR-BSA-PCL and 131 I-BSA-PCL in vitro and in vivo. 131 I-antiEGFR-BSA-PCL suppressed the development of tumors and exhibited pronounced anti-proliferation ability against the xenografted LS180 cells in a mouse model.
Applications
As a novel theranostic agent, 131 I-antiEGFR-BSA-PCL exhibited pronounced anti-tumoral effects on colorectal cancer.
Peer-review
This study evaluated the therapeutic effectiveness of 131 I-antiEGFR-BSA-PCL in the colorectal cancer mouse model and demonstrated the potential beneficial application of 131 I-antiEGFR-BSA-PCL for treating colorectal cancer. The manuscript is well written and properly conducted.
